BioCentury | Mar 23, 2015
Analyst Picks & Changes

Analyst picks & changes

...Hold (from buy) -10% $2.59 Kolbert downgraded after Synthetic Biologics announced it will not advance SYN-005...
...into the clinic. Synthetic has exclusive, worldwide rights to technologies used to develop and commercialize SYN-005...
BioCentury | Sep 22, 2014
Clinical News

SYN-005 regulatory update

...Synthetic Biologics said FDA granted Orphan Drug designation to SYN-005 to treat pertussis. In mid-2015, the...
...Texas at Austin. Intrexon Corp. (NYSE:XON), Germantown, Md. Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Product: SYN-005...
BioCentury | May 12, 2014
Clinical News

Intrexon, Synthetic Biologics preclinical data

...Synthetic Biologics said SYN-005 was associated with significant reductions in white blood cell count and bacterial...
...Texas at Austin. Intrexon Corp. (NYSE:XON), Germantown, Md. Synthetic Biologics Inc. (NYSE-M:SYN), Rockville, Md. Product: SYN-005...
Items per page:
1 - 3 of 3